Literature DB >> 30069751

Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Year:  2018        PMID： 30069751     DOI： 10.1007/s00417-018-4094-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.

Authors:  Julie Blanc; Clémence Deschasse; Laurent Kodjikian; Corinne Dot; Alain-Marie Bron; Catherine Creuzot-Garcher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-31       Impact factor: 3.117

2.  Comments to: Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Eur J Ophthalmol       Date:  2017-11-08       Impact factor: 2.597

3.  Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Can J Ophthalmol       Date:  2017-01-05       Impact factor: 1.882

4.  Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2017-02-09       Impact factor: 5.258

5.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

6.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

7.  Comment on "Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion".

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

8.  Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2017-10-09       Impact factor: 5.258

9.  Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-04       Impact factor: 3.117

10.  Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.

Authors:  David M Brown; Charles C Wykoff; Tien P Wong; Angeline F Mariani; Daniel E Croft; Karri L Schuetzle
Journal:  Retina       Date:  2014-09       Impact factor: 4.256
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.